...
【24h】

Locally advanced gallbladder cancer: Which patients benefit from resection?

机译:局部晚期胆囊癌:哪些患者可从切除术中受益?

获取原文
获取原文并翻译 | 示例

摘要

Objectives: Patients with T3-4 gallbladder cancers (GBCs) often require extended surgical procedures, and up to 30% of patients have N2 metastases. This study investigated which patients with T3-4 GBC benefit from resection. Methods: Consecutive patients (n = 78) with T3-4 GBC who underwent resection between 1990 and 2011 were analysed (38 before 2003, 40 in 2003-2011). Forty patients required common bile duct (CBD) resection, 10 pancreatoduodenectomy, 4 right colectomy and 2 gastric resection. Fifty-two (67%) patients had LN metastases, including 22 with N2 metastases. Results: The in-hospital mortality rate was 8%, 11% before 2003 vs. 5% in 2003-2011. The morbidity rate (47%) remained stable during the study. Undergoing liver and pancreatic resection did not increase severe morbidity (0%) or mortality (10%). Sixty-seven (86%) patients had R0 resection. The 5-year survival rate was 17% (median follow-up, 65 months). Survival improved after 2002 (26% vs. 9%, p = 0.04). R1 patients had poor 3-year survival (0% vs. 32%, p = 0.001). N+ patients also had low survival (5-year survival, 10% vs. 32% in N0, p = 0.019), but N1 and N2 patients had similar outcomes. CBD resection and major hepatectomy did not worsen prognosis. Patients requiring pancreatoduodenectomy, gastric or colonic resection had 0% 3-year survival (p = 0.036 in multivariate analysis). Conclusions: Resection of T3-4 GBC is worthwhile only if R0 surgery is achievable. Outcomes improved in most recent years. N2 metastases should not preclude surgery. Good results are possible even with CBD resection or major hepatectomy, while benefits from surgery are doubtful if pancreatoduodenectomy or other organ resection is needed.
机译:目的:患有T3-4胆囊癌(GBC)的患者通常需要延长手术过程,多达30%的患者患有N2转移。这项研究调查了哪些T3-4 GBC患者受益于切除术。方法:分析1990年至2011年间连续切除的T3-4 GBC患者(78例)(2003年之前为38例,2003-2011年为40例)。 40例患者需要行胆总管切除术,10例胰十二指肠切除术,4例右结肠切除术和2例胃切除术。 52例(67%)患者发生LN转移,其中22例患有N2转移。结果:院内死亡率为8%,2003年之前为11%,而2003-2011年为5%。在研究期间,发病率(47%)保持稳定。进行肝脏和胰腺切除术不会增加严重的发病率(0%)或死亡率(10%)。 67例(86%)患者接受了R0切除术。 5年生存率为17%(中位随访时间为65个月)。 2002年之后的生存率有所提高(26%比9%,p = 0.04)。 R1患者的3年生存期较差(0%比32%,p = 0.001)。 N +患者的生存率也较低(5年生存率,N0为10%,而N0为32%,p = 0.019),但是N1和N2患者的预后相似。 CBD切除术和大肝切除术并未使预后恶化。需要进行胰十二指肠切除术,胃或结肠切除术的患者3年生存率为0%(多变量分析中p = 0.036)。结论:只有可行R0手术,才应行T3-4 GBC切除术。最近几年的结局有所改善。 N2转移不应排除手术。即使采用CBD切除术或大肝切除术也可能取得良好的效果,而如果需要进行胰十二指肠切除术或其他器官切除术,则手术的益处值得怀疑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号